Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 11Breast 6Plasma cell 3Gynecologic 3Tumor-Agnostic 2Thoracic 2Other hematologic neoplasm 2Head & Neck 2Genitourinary 2Gastrointestinal 2Other solid neoplasm 1Endocrine 1Dermatologic 1CNS 1

Conditions

Malignant Solid Neoplasm 1

Interventions

pembrolizumab 75Injections 67Carboplatin 38Pemetrexed 29Cisplatin 29Nivolumab 27Specimen Handling 24Interviews as Topic 24Cyclophosphamide 24atezolizumab 21tislelizumab 20Bevacizumab 20Paclitaxel 19Standard of Care 16Practice Guidelines as Topic 16fludarabine 15Docetaxel 15toripalimab 14Ipilimumab 14Educational Status 14Cetuximab 14Fluorouracil 13Oxaliplatin 12Etoposide 12olaparib 11durvalumab 11Methods 11Gemcitabine 11Early Intervention, Educational 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
copanlisib × Other solid neoplasm × 1 year × Clear all
NCT06360588 2026-05-28

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
22 enrolled 9 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡